ATE228142T1 - Verbindungen und verfahren zur inhibierung der verbreitung der hiv - Google Patents
Verbindungen und verfahren zur inhibierung der verbreitung der hivInfo
- Publication number
- ATE228142T1 ATE228142T1 AT95111359T AT95111359T ATE228142T1 AT E228142 T1 ATE228142 T1 AT E228142T1 AT 95111359 T AT95111359 T AT 95111359T AT 95111359 T AT95111359 T AT 95111359T AT E228142 T1 ATE228142 T1 AT E228142T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- inhibiting
- spread
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 5
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/277,857 US5733781A (en) | 1994-07-19 | 1994-07-19 | Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE228142T1 true ATE228142T1 (de) | 2002-12-15 |
Family
ID=23062654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95111359T ATE228142T1 (de) | 1994-07-19 | 1995-07-19 | Verbindungen und verfahren zur inhibierung der verbreitung der hiv |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5733781A (de) |
| EP (1) | EP0697414B1 (de) |
| JP (1) | JP3307944B2 (de) |
| KR (1) | KR970704768A (de) |
| AT (1) | ATE228142T1 (de) |
| AU (1) | AU699233B2 (de) |
| CA (1) | CA2194398A1 (de) |
| DE (1) | DE69528867D1 (de) |
| WO (1) | WO1996002557A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2279673A1 (en) * | 1995-12-15 | 1997-06-16 | Enzo Therapeutics, Inc. | Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses |
| US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
| DE69727984T2 (de) * | 1996-07-09 | 2005-01-05 | Canji, Inc., San Diego | Verfahren zur messung viraler infektivität |
| US5962665A (en) * | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
| US7244570B2 (en) * | 1998-08-04 | 2007-07-17 | Luminex Molecular Diagnostics, Inc. | Methods and compositions for modulating “marginally indiscriminant” hybridizations |
| AU5067499A (en) * | 1998-08-10 | 2000-03-06 | Meiji Milk Products Co., Ltd. | Mass secretion/expression system of true mk family protein |
| DE19850186A1 (de) * | 1998-10-30 | 2000-05-25 | Roche Diagnostics Gmbh | Neue Primer und Sonden zum Nachweis von HIV |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| WO2000046403A2 (en) | 1999-02-03 | 2000-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OFHEALT H AND HUMAN SERVICES | Methods and reagents for molecular detection of hiv-1 groups m, n and o |
| KR20020069627A (ko) * | 2001-02-27 | 2002-09-05 | 동부한농화학 주식회사 | 육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도 |
| EP1411770A4 (de) | 2001-07-05 | 2006-05-10 | Chiron Corp | Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| US6852491B2 (en) * | 2001-09-04 | 2005-02-08 | Abbott Laboratories | Amplification and detection reagents for HIV-1 |
| US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US20060205070A1 (en) * | 2004-01-13 | 2006-09-14 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | HIV TEV compositions and methods of use |
| US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
| US8617816B2 (en) * | 2007-03-16 | 2013-12-31 | 454 Life Sciences, A Roche Company | System and method for detection of HIV drug resistant variants |
| EP2376633A1 (de) * | 2008-12-17 | 2011-10-19 | AVI BioPharma, Inc. | Antisense-zusammensetzungen und verfahren zur modulation von kontaktüberempfindlichkeit oder kontaktdermatitis |
| NL2010579C2 (nl) | 2013-04-05 | 2014-10-07 | Thomas Regout Internat B V | Anti-kantelsamenstel voor een reeks van laden in een gereedschapskast. |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| GB8423659D0 (en) * | 1984-09-19 | 1984-10-24 | Pasteur Institut | Cloned dna sequences |
| NZ209840A (en) * | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
| US4738922A (en) * | 1984-05-25 | 1988-04-19 | Dana Farber Cancer Institute | Trans-acting transcriptional factors |
| IL79391A (en) * | 1985-08-14 | 1994-06-24 | Hughes Aircraft Co | Non-spherical patch with a stepped key and a display system that uses it |
| US4752565A (en) | 1986-04-07 | 1988-06-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell line producing AIDS viral antigens without producing infectious virus particles |
| US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| EP0300213A1 (de) * | 1987-06-22 | 1989-01-25 | Hexal-Pharma Gentechnik GmbH & Co. KG | Virale, immunogen wirksame Peptidpartikel von Hepatitis A |
| US5110802A (en) * | 1987-07-14 | 1992-05-05 | City Of Hope | Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates |
| DE3854029T2 (de) | 1987-09-21 | 1995-10-26 | Gen Probe Inc | Homogener Abschirmungstest. |
| IL89993A0 (en) * | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Expression of the hiv 24kda gag protein in methylotrophic yeasts |
| US5449769A (en) | 1989-03-06 | 1995-09-12 | Gen-Probe Incorporated | Method and reagent for sulfurization of organophosphorous compounds |
| ATE423856T1 (de) * | 1989-06-02 | 2009-03-15 | Pasteur Institut | Nukleotid-sequenzen von hiv-1, hiv-2 und siv retrovirusgenomen, ihre verwendung zur amplifizierung von pol-sequenzen dieser retroviren und zur in vitro diagnostik von diesen viren verursachten infektionen |
| US5144019A (en) * | 1989-06-21 | 1992-09-01 | City Of Hope | Ribozyme cleavage of HIV-I RNA |
| IE910081A1 (en) * | 1990-01-10 | 1991-07-17 | Chiron Corp | The use of DNA-dependent RNA polymerase transcripts as¹reporter molecules for signal amplification in nucleic acid¹hybridization assays |
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| EP0592434B1 (de) | 1990-10-26 | 1998-10-07 | Genta Incorporated | Verbessertes verfahren zur synthese von oligomeren |
| WO1992016180A2 (en) * | 1991-03-13 | 1992-10-01 | Siska Diagnostics, Inc. | Detection of 3'-azido-3'-deoxythymidine resistance |
| US5226326A (en) * | 1991-05-31 | 1993-07-13 | Environmental Stress Screening Corp. | Vibration chamber |
| FR2677039B1 (fr) * | 1991-05-31 | 1994-09-09 | Cis Bio Int | Oligonucleotides, utilisables comme reactifs pour la detection in vitro des infections a retrovirus de type hiv et procede de detection de retrovirus de type hiv. |
| CA2124797C (en) * | 1991-12-23 | 2004-03-30 | Bruce D. Irvine | Hiv probes for use in solution phase sandwich hybridization assays |
| US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| DK0664833T3 (da) * | 1992-10-05 | 1997-04-14 | Hybridon Inc | Terapeutisk anti-HIV oligonukletid og lægemiddel |
| KR100325554B1 (ko) * | 1993-03-26 | 2002-11-02 | 젠-프로브 인코포레이티드 | 사람의면역결핍 바이러스타입1의검출 |
| CN101400315B (zh) | 2006-03-09 | 2013-03-27 | 3M创新有限公司 | 材料分配器件 |
| CN101689633A (zh) | 2007-05-08 | 2010-03-31 | 加利福尼亚大学董事会 | 高放电倍率锂离子电池 |
| US8803361B2 (en) | 2011-01-19 | 2014-08-12 | Schneider Electric It Corporation | Apparatus and method for providing uninterruptible power |
| US9202037B2 (en) | 2012-06-08 | 2015-12-01 | General Electric Company | System and method for using machine readable code to commission device applications |
-
1994
- 1994-07-19 US US08/277,857 patent/US5733781A/en not_active Expired - Lifetime
-
1995
- 1995-07-14 JP JP50524296A patent/JP3307944B2/ja not_active Expired - Fee Related
- 1995-07-14 AU AU31354/95A patent/AU699233B2/en not_active Ceased
- 1995-07-14 WO PCT/US1995/009080 patent/WO1996002557A1/en not_active Ceased
- 1995-07-14 CA CA002194398A patent/CA2194398A1/en not_active Abandoned
- 1995-07-19 DE DE69528867T patent/DE69528867D1/de not_active Expired - Lifetime
- 1995-07-19 AT AT95111359T patent/ATE228142T1/de not_active IP Right Cessation
- 1995-07-19 EP EP95111359A patent/EP0697414B1/de not_active Expired - Lifetime
-
1997
- 1997-01-18 KR KR1019970700344A patent/KR970704768A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10501421A (ja) | 1998-02-10 |
| CA2194398A1 (en) | 1996-02-01 |
| EP0697414A1 (de) | 1996-02-21 |
| US5733781A (en) | 1998-03-31 |
| EP0697414B1 (de) | 2002-11-20 |
| AU3135495A (en) | 1996-02-16 |
| DE69528867D1 (de) | 2003-01-02 |
| JP3307944B2 (ja) | 2002-07-29 |
| AU699233B2 (en) | 1998-11-26 |
| WO1996002557A1 (en) | 1996-02-01 |
| KR970704768A (ko) | 1997-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE228142T1 (de) | Verbindungen und verfahren zur inhibierung der verbreitung der hiv | |
| DE69432635D1 (de) | Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus | |
| DE69830751D1 (de) | Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen | |
| BG100455A (en) | Hiv protease inhibitors | |
| FI946066L (fi) | Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina | |
| HU901585D0 (en) | Method for treatment of viral infections using functional derivatives of icam-1 | |
| ATE142873T1 (de) | Hemmung einer virusinfektion | |
| ATE312079T1 (de) | Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion | |
| IL193148A0 (en) | Use of combinations of agents for the preparation of medicaments for treatment of hepatitis b virus | |
| ATE235495T1 (de) | 8-arylalkyl- und 8-arylheteroalkyl-5, 11-dihydro- 6h-dipyrido-(3,2-b:2', 3'-e)(1,4)diazepine und ihre verwendung zur vorbeugung oder behandlung von hiv-infektion | |
| ATE521361T1 (de) | Verfahren zur behandlung von gebärmutterhalskrebs | |
| ATE245444T1 (de) | Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen | |
| DE69829217D1 (de) | Vorrichtung zur therapeutischen behandlung von blutgefässen | |
| EE03514B1 (et) | Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon | |
| DE69307674D1 (de) | HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS | |
| WO1999051256A3 (en) | Use of l-glu-l-trp in the treatment of hiv infection | |
| ATA113492A (de) | Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven | |
| ATE281173T1 (de) | Behandlung einer virusinfektion bei schweinen | |
| UA41338C2 (uk) | Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл) | |
| ATE412423T1 (de) | Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion | |
| WO1998044913A3 (en) | Compositions containing mkc-442 in combination with other antiviral agents | |
| DE60002172D1 (de) | Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopenten-1-methanol in hbv | |
| ATE56878T1 (de) | Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen. | |
| DE19980721D2 (de) | CD4-Radioimmunpharmaka zur Behandlung der HIV-Infektion | |
| RU92014469A (ru) | Средство для определения степени аттенуации вируса полиомиелита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |